



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

## Public Summary

<b>Summary for ARTG Entry:</b>	315375	ACTIVATED PROBIOTICS BIOME IBS
<b>ARTG entry for</b>	Medicine Listed	
<b>Sponsor</b>	Biome Australia Limited	
<b>Postal Address</b>	192/194 Johnston Street, Collingwood, VIC, 3066 Australia	
<b>ARTG Start Date</b>	13/03/2019	
<b>Product Category</b>	Medicine	
<b>Status</b>	Active	
<b>Approval Area</b>	Listed Medicines	

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . ACTIVATED PROBIOTICS BIOME IBS

<b>Product Type</b>	Single Medicine Product	<b>Effective Date</b>	18/04/2020
---------------------	-------------------------	-----------------------	------------

#### Permitted Indications

Enhance/improve/promote/increase bowel regularity

Relief of symptoms of medically diagnosed Irritable Bowel Syndrome in adults

Decrease/reduce/relieve abdominal bloating/distention in adults

#### Indication Requirements

Label statement: Do not use when abdominal pain, nausea or vomiting are present or if you develop diarrhoea. If you are pregnant or breastfeeding - seek the advice of a healthcare professional before taking this product (or words to that effect).

Label statement: Drink plenty of water (or words to that effect).

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to gastro oesophageal reflux disease.

Product presentation must not refer to or imply weight loss.

Product presentation must only refer to medically diagnosed IBS.

Label statement for stimulant laxatives: Prolonged use may cause serious bowel problems.

Label statement: If symptoms persist or worsen talk to your medical practitioner.

#### Standard Indications

No Standard Indications included on Record

#### Specific Indications

No Specific Indications included on Record

#### Warnings

Do not use if pregnant or likely to become pregnant (or words to that effect)

#### Additional Product information

Public Summary



**Australian Government**  
**Department of Health and Aged Care**  
Therapeutic Goods Administration

**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Blister Pack	Not recorded	Not recorded	Not recorded	Neither child resistant closure nor restricted flow insert	Not recorded

**Pack Size/Poison information**

Pack Size	Poison Schedule
-----------	-----------------

**Components**

**1 . Formulation 1**

**Dosage Form** Capsule, hard

**Route of Administration** Oral

**Visual Identification**

**Active Ingredients**

Bifidobacterium breve	3 billion CFU
Lactobacillus plantarum	10 billion CFU
Lactobacillus rhamnosus	10 billion CFU

**Other Ingredients (Excipients)**

hypromellose  
maltodextrin  
silicon dioxide  
titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary